EASTHAM KARIN sold $197K of VCYT
EASTHAM KARIN sold 3,729 shares of VERACYTE, INC. (VCYT) at an average of $52.89 ($52.78–$53.55, $0.20M total) across 2 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale details (shares, price range, total value) and that it was executed under a 10b5-1 plan.
Market read
This is a disclosed insider sale; it may cause minor sentiment noise but lacks fundamental new information.
What to watch
The filing does not disclose any new company performance, guidance, or operational event—so traders should avoid over-weighting it versus upcoming fundamentals.
Background
SEC Form 4 reports an insider transaction by a director of Veracyte, Inc. (VCYT).
Ticker impact
Veracyte director Eastham Karin filed a Form 4 selling 3,729 shares in open-market trades on 2026-06-18 under a 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely muted and short-lived.
The filing is a disclosed insider transaction (director, open-market sale) with a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
Minimal; this is company-specific insider trading with no sector-wide regulatory/operational change.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerVERACYTE, INC.
Company whose director insider sale was reported on SEC Form 4.
- insiderEASTHAM KARIN
Director who sold 3,729 shares in open-market transactions on 2026-06-18.